Roivant Sciences Ltd. (ROIV)
| Market Cap | 3.07B |
| Revenue (ttm) | 55.29M |
| Net Income (ttm) | -845.26M |
| Shares Out | 703.22M |
| EPS (ttm) | -4.52 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 250,959 |
| Open | 4.48 |
| Previous Close | 4.46 |
| Day's Range | 4.37 - 4.55 |
| 52-Week Range | 2.52 - 16.76 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 11.80 (+170.0%) |
| Earnings Date | Aug 15, 2022 |
About ROIV
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom. [Read more...]
Financial Performance
In 2021, ROIV's revenue was $55.29 million, an increase of 132.34% compared to the previous year's $23.80 million. Losses were -$845.26 million, 4.45% more than in 2020.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ROIV stock is "Buy." The 12-month stock price forecast is 11.8, which is an increase of 170.02% from the latest price.
News
Roivant Sciences to Report Financial Results for the Quarter Ended June 30, 2022 on Monday, August 15, 2022
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Aug. 03, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to...
Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides B...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 28, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the deli...
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomy...
NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences and Pfizer today announced the unveiling of Priovant Therapeutics, dedicated to developing and commercializing novel therapies for autoimmune...
Roivant Sciences to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 on Tuesday, ...
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, June 15, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to...
FDA Approves Dermavant's VTAMA® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical ...
- EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly statistically significant improvement versus vehicle in Physician G...
Roivant to Present at Upcoming Investor Conferences
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) will participate in four upcoming healthcare investor conferences:
VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein Degraders
NEW YORK and INGELHEIM, Germany, April 20, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, and Boehringer Ingelheim today announced that the two companies have entered into an ea...
VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with Janssen
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- VantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of...
Dermavant Showcases New Long-Term Durability and Tolerability Data from Phase 3 PSOARING 3 Trial of Tapinarof Cream f...
LONG BEACH, Calif., and BASEL, Switzerland, March 25, 2022 (GLOBE NEWSWIRE) -- Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative thera...
Roivant to Present at Targeted Protein Degradation Conference
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, March 11, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV) today announced that its CEO Matt Gline will present at Guggenheim's Targeted Pr...
Andreas Halvorsen Loads Up on Health Care, Tech Stocks
Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed his portfolio for the final quarter of 2021 last week.
Roivant Sciences Reports Financial Results for the Quarter Ended December 31, 2021 and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the deli...
Roivant to Report Financial Results for the Quarter Ended December 31, 2021 on Monday, February 14, 2022
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to...
TandemAI Announces Expansion of Senior Leadership Team
NEW YORK & SUZHOU & SHANGHAI, China--(BUSINESS WIRE)--TandemAI announced it has expanded its senior leadership team with the appointments of Albert Pan, Ph.D. to CTO and Lanny Sun to Chairman
Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery ...
Full-Life Technologies Announces Senior Executive Team Appointments
BOSTON & BRUSSELS & SHANGHAI--(BUSINESS WIRE)--Full-Life Technologies, a new, fully integrated nuclear health company, announces senior executive team appointments
Roivant Sciences Reports Financial Results for the Quarter Ended September 30, 2021 and Provides Business Update
BASEL, Switzerland and LONDON and NEW YORK and BOSTON, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences Ltd. (Nasdaq: ROIV), a next-generation biopharmaceutical company dedicated to improving the deli...
Roivant to Report Financial Results for the Quarter Ended September 30, 2021 on Monday, November 15, 2021
BASEL, Switzerland, LONDON, NEW YORK and BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Roivant Sciences (Nasdaq: ROIV), a biopharmaceutical company dedicated to improving the delivery of healthcare to patie...
Roivant Discovery Announces 2021 Open Science Fellows
NEW YORK & BOSTON--(BUSINESS WIRE)-- #biotech--Roivant Discovery announces 2021 Open Science Fellows – Dr. Gregory R. Bowman, Dr. Alex Dickson and Dr. Paul Robustelli.
Why Roivant Sciences Stock Is Soaring Today
Three analysts initiated positive coverage on the biotech stock.
Roivant Provides Corporate Updates
NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health,...
2 Best Biotech Stocks to Buy Now
Here's how a drug discovery company and a coronavirus vaccine drugmaker can boost investors' portfolios.
'SPACs Attack' Recap: Looking Back At 5 SPAC Deals, Rumors And Top Headlines
Last week featured five announced SPAC deals and several rumors. The week also had earnings from several well-known former SPACs.
Roivant Sciences Gets SPAC Deal: What To Expect From This BioPharma, Health Technology Company
A drug discovery company with ownership stakes in several public and private biopharmaceutical companies is going public with a SPAC deal announced Monday morning. The SPAC Deal: Roviant Sciences announ...
Roivant Sciences and Montes Archimedes Acquisition Corp. (MAAC) to Combine and Create Publicly Traded Leader in Bioph...
NEW YORK, MENLO PARK, Calif., LONDON, and BASEL, Switzerland, May 3, 2021 /PRNewswire/ -- Roivant Sciences, a biopharmaceutical and healthcare technology company, and Montes Archimedes Acquisition Corp....